Alector reported a quarterly loss of $0.34 per share, surpassing the expected loss with a 13.71% earnings surprise.The company's revenue for the quarter was $6.24 million, significantly exceeding expectations by 103.43%.Alector's financial position is bolstered by $256 million in cash and equivalents, with a current ratio of 3.83, indicating a strong ability to cover short-term liabilities.Alector, Inc. (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenera ...

Core Viewpoint - Annovis Bio, Inc. is hosting a corporate update webinar to discuss recent progress, ongoing clinical programs, and strategic directions in the development of therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2][3] Group 1: Webinar Details - The webinar will be presented by Maria Maccecchini, Ph.D., President and CEO, who will provide a comprehensive update on the company's journey and future plans [2][3] - The event is scheduled for January 28, 2026, at 4:30 p.m. ET, and is open to shareholders, patients, investigators, and other interested parties [7] - Participants are encouraged to submit questions in advance via email [3] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on developing innovative therapies aimed at improving patient outcomes in neurodegenerative diseases [4] - The company is committed to addressing conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD) [4]